image credit: Pexels

Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

May 20, 2024


Haemophilia A is a rare hereditary bleeding disorder that occurs when there is a lack of sufficient functioning factor VIII protein to help the blood clot, leading to external bleeding, bruising and bleeding into joints.

Designed to extend protection from bleeding, Altuviiio allows for weekly dosing as it has a half-life that is up to four times longer than standard and extended half-life factor VIII products.

Read More on PMLiVE